361 related articles for article (PubMed ID: 35770532)
21. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
Front Immunol; 2021; 12():693200. PubMed ID: 34290712
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
[TBL] [Abstract][Full Text] [Related]
24. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Zhang J; Li J; Ma Q; Yang H; Signorovitch J; Wu E
Adv Ther; 2020 Jul; 37(7):3040-3058. PubMed ID: 32524498
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
[TBL] [Abstract][Full Text] [Related]
26. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
27. Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience.
Casadei B; Argnani L; Guadagnuolo S; Pellegrini C; Stefoni V; Broccoli A; Nanni L; Morigi A; Lolli G; Guarino M; Spinardi L; Pierucci E; Fanti S; Bartoletti M; Dicataldo M; Sabattini E; Bonifazi F; Zinzani PL
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638273
[TBL] [Abstract][Full Text] [Related]
28. Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR.
Badbaran A; Berger C; Riecken K; Kruchen A; Geffken M; Müller I; Kröger N; Ayuk FA; Fehse B
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698364
[TBL] [Abstract][Full Text] [Related]
29. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
Sim AJ; Jain MD; Figura NB; Chavez JC; Shah BD; Khimani F; Lazaryan A; Krivenko G; Davila ML; Liu HD; Falchook AD; Dahiya S; Rapoport AP; Kim S; Locke FL; Robinson TJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1012-1021. PubMed ID: 31175906
[TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A
Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993
[TBL] [Abstract][Full Text] [Related]
31. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
[TBL] [Abstract][Full Text] [Related]
32. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT
Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873
[TBL] [Abstract][Full Text] [Related]
33. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
[TBL] [Abstract][Full Text] [Related]
34. CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
Kuhnl A; Kirkwood AA; Roddie C; Menne T; Tholouli E; Bloor A; Besley C; Chaganti S; Osborne W; Norman J; Gibb A; Sharplin K; Cuadrado M; Correia de Farias M; Cheok K; Neill L; Latif AL; González Arias C; Uttenthal B; Jones C; Johnson R; McMillan A; Sanderson R; Townsend W
Br J Haematol; 2023 Jul; 202(1):65-73. PubMed ID: 37082780
[TBL] [Abstract][Full Text] [Related]
35. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Lunning MA; Wang HL; Hu ZH; Locke FL; Siddiqi T; Jacobson CA; Ahmed S; Miklos DB; Lin Y; Hill BT; Ghobadi A; Neelapu SS; Westin J; Dieyi C; Field P; Miao H; Shahani SA; Patel A; Spooner C; Fu C; Muramoto D; Xu H; Pasquini MC
Am J Hematol; 2024 May; 99(5):880-889. PubMed ID: 38504387
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain.
Bastos-Oreiro M; de Las Heras A; Presa M; Casado MA; Pardo C; Martín-Escudero V; Sureda A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158805
[TBL] [Abstract][Full Text] [Related]
37. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
Jacobson CA; Locke FL; Ma L; Asubonteng J; Hu ZH; Siddiqi T; Ahmed S; Ghobadi A; Miklos DB; Lin Y; Perales MA; Lunning MA; Herr MM; Hill BT; Ganguly S; Dong H; Nikiforow S; Hooper M; Kawashima J; Xu H; Pasquini MC
Transplant Cell Ther; 2022 Sep; 28(9):581.e1-581.e8. PubMed ID: 35609867
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma.
Steiner RE; Banchs J; Koutroumpakis E; Becnel M; Gutierrez C; Strati P; Pinnix CC; Feng L; Rondon G; Claussen C; Palaskas N; Karimzad K; Ahmed S; Neelapu SS; Shpall E; Wang M; Vega F; Westin J; Nastoupil LJ; Deswal A
Haematologica; 2022 Jul; 107(7):1555-1566. PubMed ID: 34758610
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
[TBL] [Abstract][Full Text] [Related]
40. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.
Haderbache R; Warda W; Hervouet E; da Rocha MN; Trad R; Allain V; Nicod C; Thieblemeont C; Boissel N; Varlet P; Agha IY; Bouquet L; Guiot M; Venet F; Sujobert P; Roussel X; Rouzaire PO; Caillot D; Casasnovas O; Bories JC; Bachy E; Caillat-Zucman S; Deschamps M; Ferrand C
J Transl Med; 2021 Jun; 19(1):265. PubMed ID: 34154602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]